Alison Moskowitz, MD, is a Medical Oncologist at the Memorial Sloan Kettering Cancer Center, New York, NY. Dr Moskowitz obtained her medical degree from Albert Einstein College of Medicine, New York, NY, qualifying in 2003. She then completed her residency in internal medicine at the Columbia University Medical Center, New York, NY, in 2006, followed by her residency in hematology/oncology at the Memorial Sloan Kettering Cancer Center, New York, NY, in 2010.
Dr Moskowitz holds membership for various societies, namely the American Medical Association (AMA), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH).
Speaking on Hodgkin lymphoma and T-cell lymphoma
Dr Moskowitz is an investigator of several clinical trials exploring therapeutic strategies for the treatment of lymphomas. She is involved in a Phase I study of nivolumab immunotherapy for high-risk Hodgkin lymphoma, two Phase II trials studying pembrolizumab immunotherapy for persistent Hodgkin lymphoma, and a Phase II trial of ruxolitinib in patients with persistent T-cell lymphoma.